文献速递脑血管病

血小板糖蛋白VI抑制在急性缺血性卒中中的安全性与有效性(ACTIMIS):一项随机、双盲、安慰剂对照的1b/2a期试验

Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
PubMed 文献 · Lancet Neurol · 2024-01-01

ACTIMIS是一项在6个欧洲国家26个卒中中心进行的随机双盲安慰剂对照1b/2a期试验,评估格伦佐西单抗(glenzocimab)联合阿替普酶±机械取栓治疗急性缺血性卒中的安全性和有效性。1b期60例患者随机接受125、250、500、1000 mg格伦佐西单抗或安慰剂,1000 mg耐受良好并选为2a期推荐剂量;2a期106例随机接受1000 mg格伦佐西单抗或安慰剂。2a期格伦佐西单抗组无症状性出血转化17/54(31%) vs 安慰剂组26/52(50%),症状性颅内出血0例 vs 5例(10%),全因死亡4例(7%) vs 11例(21%)。

要点

  • 格伦佐西单抗1000 mg联合阿替普酶±机械取栓耐受良好,可能减少严重不良事件、颅内出血和死亡。
  • 2a期症状性颅内出血格伦佐西单抗组0例 vs 安慰剂组5例(10%)。
  • 2a期全因死亡格伦佐西单抗组4例(7%) vs 安慰剂组11例(21%)。

核心结论

  • 格伦佐西单抗1000 mg联合阿替普酶±机械取栓耐受良好,可能减少严重不良事件、颅内出血和死亡。
  • 这些发现支持未来研究格伦佐西单抗联合阿替普酶对糖蛋白VI的潜在治疗性抑制。

研究设计与样本

  • 随机、双盲、安慰剂对照的剂量递增(1b期)和剂量确认(2a期)研究(ACTIMIS),在6个欧洲国家的26个卒中中心进行。
  • 纳入年龄≥18岁、致残性急性缺血性卒中且阿替普酶给药前美国国立卫生研究院卒中量表评分≥6分的患者。
  • 1b期60例患者随机接受125 mg、250 mg、500 mg、1000 mg格伦佐西单抗或安慰剂(每组n=12),均纳入安全性分析。
  • 2a期106例患者随机接受格伦佐西单抗1000 mg(n=53)或安慰剂(n=53);安慰剂组1例误接受格伦佐西单抗,安全性集分别为54例和52例。
  • 治疗在卒中症状发作后4.5小时或更早启动,患者接受阿替普酶伴或不伴机械取栓。

主要发现

  • 1b期中格伦佐西单抗1000 mg耐受良好,被选为2a期推荐剂量。
  • 2a期最常见的治疗中出现的不良事件为无症状性出血转化,格伦佐西单抗组17/54(31%) vs 安慰剂组26/52(50%)。
  • 2a期症状性颅内出血格伦佐西单抗组0例 vs 安慰剂组5例(10%)。
  • 2a期全因死亡格伦佐西单抗组4例(7%) vs 安慰剂组11例(21%)。

关键数值与推荐

  • 1b期剂量组:125 mg、250 mg、500 mg、1000 mg格伦佐西单抗或安慰剂,每组n=12。
  • 2a期推荐剂量:格伦佐西单抗1000 mg。
  • 2a期安全性集:格伦佐西单抗组54例,安慰剂组52例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antagonists of glycoprotein VI-triggered platelet activation used in combination with recanalisation therapies are a promising therapeutic approach in acute ischaemic stroke. Glenzocimab is an antibody fragment that inhibits the action of platelet glycoprotein VI. We aimed to determine and assess the safety and efficacy of the optimal dose of glenzocimab in patients with acute ischaemic stroke eligible to receive alteplase with or without mechanical thrombectomy. METHODS: This randomised, double-blind, placebo-controlled study with dose-escalation (1b) and dose-confirmation (2a) phases (ACTIMIS) was done in 26 stroke centres in six European countries. Participants were adults (≥18 years) with disabling acute ischaemic stroke with a National Institutes of Health Stroke Scale score of 6 or higher before alteplase administration. Patients were randomly assigned treatment using a central electronic procedure. Total administered dose at the end of the intravenous administration was 125 mg, 250 mg, 500 mg, and 1000 mg of glenzocimab or placebo in phase 1b and 1000 mg of glenzocimab or placebo in phase 2a. Treatment was initiated 4·5 h or earlier from stroke symptom onset in patients treated with alteplase with or without mechanical thrombectomy. The sponsor, study investigator and study staff, patients, and central laboratories were all masked to study treatment until database lock. Primary endpoints across both phases were safety, mortality, and intracranial haemorrhage (symptomatic, total, and fatal), assessed in all patients who received at least a partial dose of study medication (safety set). The trial is registered on ClinicalTrials.gov, NCT03803007, and is complete. FINDINGS: Between March 6, 2019, and June 27, 2021, 60 recruited patients were randomly assigned to 125 mg, 250 mg, 500 mg, or 1000 mg glenzocimab, or to placebo in phase 1b (n=12 per group) and were included in the safety analysis. Glenzocimab 1000 mg was well tolerated and selected as the phase 2a recommended dose; from Oct 2, 2020, to June 27, 2021, 106 patients were randomly assigned to glenzocimab 1000 mg (n=53) or placebo (n=53). One patient in the placebo group received glenzocimab in error and therefore 54 and 52, respectively, were included in the safety set. In phase 2a, the most frequent treatment-emergent adverse event was non-symptomatic haemorrhagic transformation, which occurred in 17 (31%) of 54 patients treated with glenzocimab and 26 (50%) of 52 patients treated with placebo. Symptomatic intracranial haemorrhage occurred in no patients treated with glenzocimab compared with five (10%) patients in the placebo group. All-cause deaths were lower with glenzocimab 1000 mg (four [7%] patients) than with placebo (11 [21%] patients). INTERPRETATION: Glenzocimab 1000 mg in addition to alteplase, with or without mechanical thrombectomy, was well tolerated, and might reduce serious adverse events, intracranial haemorrhage, and mortality. These findings support the need for future research into the potential therapeutic inhibition of glycoprotein VI with glenzocimab plus alteplase in patients with acute ischaemic stroke. FUNDING: Acticor Biotech.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Mazighi M, Köhrmann M, Lemmens R, et al. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial. Lancet Neurol. 2024. PMID: 38267188. doi:10.1016/S1474-4422(23)00427-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。